Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HA1 | P13674 | 2/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822487 | 0.86 | P4HA1 (0.53) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL30521254 | 0.85 | P4HA1 (0.52) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL25804618 | 0.85 | P4HA1 (0.52) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL15718539 | 0.85 | P4HA1 (0.52) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL600427 | 0.85 | P4HA1 (0.52) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL5366444 | 0.84 | KCNJ1 (0.44) | P4HA1P4HTMALDH1A1HPGDMAPT | |
| SCHEMBL10034527 | 0.82 | CLK1 (0.39) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL12775299 | 0.82 | NNMT (0.55) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL3485657 | 0.82 | NAPRT (0.41) | P4HA1P4HTMMIFNAPRTALDH1A1 | |
| SCHEMBL25890668 | 0.82 | ALDH1A1 (0.49) | P4HA1P4HTMMIFGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3444251-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7132426-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006053121-A2 | IMIDAZO[1 , 2-A] PYRAZIN-8-YLAMINES USEFUL AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1644375-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005007658-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142262-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | P4HA1 322/4885P4HTM 373/4885MIF 2928/4885 |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | P4HA1 3308/4885P4HTM 1230/4885MIF 3727/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | P4HA1 4061/4885P4HTM 3848/4885MIF 411/4885 |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | P4HA1 3308/4885P4HTM 1230/4885MIF 3727/4885 |
| US-12358929-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | P4HA1 3308/4885P4HTM 1230/4885MIF 3727/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | P4HA1 3172/4885P4HTM 3239/4885MIF 2660/4885 |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | P4HA1 3172/4885P4HTM 3239/4885MIF 2660/4885 |
| US-20060178367-A1 | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | BTK, SYK, LCK | P4HA1 3472/4885P4HTM 4060/4885MIF 209/4885 |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | P4HA1 322/4885P4HTM 373/4885MIF 2928/4885 |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | P4HA1 322/4885P4HTM 373/4885MIF 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.